<DOC>
	<DOCNO>NCT02536586</DOCNO>
	<brief_summary>The main purpose study evaluate tolerability investigational drug know LY3023414 Japanese participant advanced cancer cancer spread another part ( ) body . The study also explore safety drug . It measure much drug get blood steam long body take get rid . It investigate anti-cancer activity .</brief_summary>
	<brief_title>A Study LY3023414 Japanese Participants With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Have histological cytological evidence diagnosis solid tumor advance and/or metastatic must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail standard therapy would appropriate . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Have adequate organ coagulation function . Have discontinue previous cancer therapy , agent receive regulatory approval indication , least 21 day 5 halflives prior study treatment , whichever short , recover acute effect therapy . Participants must discontinue mitomycinC nitrosourea therapy least 42 day . Are able swallow capsule . Males must agree use medically approve barrier contraceptive precaution study 3 month follow last dose study drug . Females childbearing potential : Must agree use medically approve contraceptive precaution study 3 month follow last dose study drug , must negative serum urine pregnancy test ≤7 day first dose study drug . A breastfeed woman must breastfeed . If female stop breastfeed enters study , breastfeed must cease day first study drug administration least 3 month last administration . Exclusion Criteria Have serious preexist medical condition . Have symptomatic central nervous system malignancy metastasis . Have know acute chronic leukemia current hematologic malignancy , judgment investigator sponsor , may affect interpretation result . Have know active fungal , bacterial , and/or know viral infection . Intolerance previous treatment phosphatidylinositol 3kinase ( PI3K ) /AKT/mammalian target rapamycin ( mTOR ) inhibitor . Treatment PI3K/AKT/mTOR inhibitor must discontinue least 21 day 5 halflives prior first study drug administration , whichever short , participant must recover acute effect therapy . Have second primary malignancy , judgment investigator , sponsor may affect interpretation result . Participants active alcohol abuse , determine investigator . Have history heart failure accord New York Heart Association Class ≥3 . Have correct QT ( QTc ) interval &gt; 470 millisecond ( msec ) screen electrocardiogram ( ECG ) . Have insulindependent diabetes mellitus history gestational diabetes mellitus . Have evidence clinically active interstitial lung disease ( ILD ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>